A blocking enzyme-linked immunosorbent assay (ELISA) test has been developed to distinguish pseudorabies virus (PRV)-infected pigs from those immunized with a glycoprotein g92(gIII) deletion mutant, PRV(dlg92dltk). The blocking ELISA utilizes 96-well microtiter test plates coated with a cloned PRV g92(gIII) antigen, a mouse monoclonal antibody against gIII antigen (moMCAgIII) : horseradish peroxidase (HRPO) conjugate, and undiluted test sera. Analyses can be completed in less than 3 hours with results printed out by an automated plate reader. Analyses on over 300 pig sera from PRV-free farms, on sera from other species, and on control sera containing antibodies to microorganisms other than PRV showed that the ratio of the optical density at 405 nm for the test sample to the optical density at 405 nm for the negative control (S/N value) was >0.7 for all sera. No false positives were identified. Likewise, the S/N values were >0.7 for over 400 sera obtained from pigs vaccinated twice with more than 1,000 times the standard PRV (dlg92dltk) dose or l-4 times with the standard dose (2 x l0 5 TCID 50 /pig). Following challenge exposure to virulent PRV, the S/N values of the vaccinates were 0.1, showing that g92(gIII) antibodies in the sera of experimentally challenged pigs strongly blocked the binding of the moMCAgIII: HRPO conjugate to the antigen-coated wells. Sera of 233 pigs from PRV-infected herds with virus neutralization (VN) titers of 1:4 or greater were tested. All except 2 of these sera had S/N values <0.7 and more than 175 had S/N values <0.1. Sixteen sera from feral pigs with VN titers of 1:4 or greater had S/N values of 0.24 or less, but 2 sera with VN titers of 1:4 when tested 5 years prior to the PRV g92(gIII) blocking ELISA test gave false negative S/N values. Twenty-four of 29 pig sera from PRV-infected herds with VN titers < 1:4 were positive for g92(gIII) antibodies, illustrating the sensitivity of the PRV g92(gIII) blocking ELISA test. Analyses on 7 sera with VN titers of 1:4-1:64 showed that titers obtained with the PRV g92(gIII) blocking ELISA test were from 2-to 16-fold greater than the VN titers. The accuracy and sensitivity of the PRV g92(gIII) blocking ELISA test was further demonstrated by analyses of 40 unknown sera supplied in the National Veterinary Services Laboratories 1988 PRV check test kit.
We have previously described a genetically engi-gIII antigen (moMCAgIII) : horseradish peroxidase neered modified-live virus "marker vaccine" 7,l0-l2 that (HRPO) conjugate, plus ABTS c for color development. enables veterinarians to distinguish vaccinated pigs Analyses can be completed in 3 hours. The test has 2 from those infected with pseudorabies virus (PRV) novel features. First, it utilizes a cloned PRV g92(gIII) by using serological tests. This PRV vaccine, antigen to coat wells of microtiter test plates, and, sec-PRV(dlg92dltk), a was derived from a thymidine kinase ond, undiluted serum is utilized in the test to block (TK) deletion mutant of the Bucharest strain of PRV the binding of the moMCAg92 : HRPO conjugate to (PRV[BUK-dl3b]), b but, in addition to the TK delethe antigen. tion, it harbors a deletion in the major PRV envelope glycoprotein gene, g92 or gIII. 9 
PRV(dlg92dltk), like
Materials and methods its immediate TK-negative parent, PRV(BUK-d13b), can safely be used to immunize newborn piglets and Preparation of PRV g92(gIII) antigen extracts. Approx- pregnant sows in all stages of gestation against pseu-imately 10 7 Madin-Darby bovine kidney (MDBK) cells were dorabies (Aujeszky's) disease. l5 The purpose of this inoculated into 6 plastic roller bottles, d 200 ml of growth report is to describe a sensitive and accurate blocking medium (consisting of Eagle's minimal essential medium ELISA C test for use in conjunction with PRV(dlg92dltk).
[APMEM] e supplemented with 2 mM glutamine, 20 mM NaHCO 3 , 10 mM HEPES buffer, pH 7.3,50 µg/ml neomycin,
The test utilizes a mouse monoclonal antibody against and 10% fetal bovine serum) was added, and the cultures were incubated at 37 C for 5 days to obtain subconfluent monolayers. The medium was removed and the cells were From the Division of Biochemical Virology, Baylor College of infected with 10 ml/bottle (about 7 x l0 8 
virus (bovine herpes virus type 1 [IBRV, BHV-1]) vector,
Received for publication April 28, 1989. designated IBRV/PRVgIII + (US patent pending). This vector virus was genetically engineered from an attenuated thymidine kinase-negative, gIII-negative IBRV strain, which in turn was derived from IBRV(Los Angeles). 6 The vector has the PRV g92(gIII) gene 8 inserted in the IBRV genome and efficiently expresses the PRV g92/gIII glycoprotein. To prepare negative control extracts not expressing PRV g92(gIII), MDBK cells were infected in the same way with IBRV(Los Angeles).
After a 1 -hr virus absorption period at 37 C, 100 ml/bottle of fresh growth medium was added, and the virus-infected cells were incubated at 37 C for 2-3 more days, at which time the monolayers showed extensive cytopathic effects. The cells were scraped from the bottles with a rubber policeman and centrifuged at 8,000 rpm for 20 min in the GSA centrifuge rotor to sediment the cells. The supernatant was discarded, the cells were resuspended in phosphate-buffered saline solution (PBS), pH 7.0, transferred to 15-ml graduated centrifuge tubes, and centrifuged at about 560 x g for 10 min at room temperature. The volume of the sedimented cells was recorded, the cells were resuspended and stirred in 3 vol of extraction buffer (0.15 M NaCl, 0.01 M borate buffer, pH 8.6, and 1% [v/v] Triton X-100), transferred to 10-ml polypropylene tubes, d and sonicated at 4 C. The PRV g92(gIII) antigen extract and the negative control extracts were then distributed to plastic tubes in l-ml aliquots and stored at -80C.
Coating of wells. Triton X-100 extracts containing the PRV g92/gIII antigen (or control extracts from IBRV(Los Angeles)-infected MDBK cells lacking this antigen) were diluted about 1:1,000 (as determined by a titration trial coating process) f with coating buffer, f and 0.1 -ml aliquots were added to the wells of 96-well flat-bottom microtiter plates.' The plates were then incubated overnight at 4 C. The supernatant fluid was removed, 0.3 ml blocking solution (2% casein [w/v] dissolved in PBS-minus solution [PBS without calcium or magnesium]) was added to each well, and the plates were further incubated overnight at 4 C. The supernatant was again dumped and the inverted plates were touched to absorbent paper. The plates were then stored at -20 C or at 4 C prior to use.
'Virus neutralization titers. Virus neutralization (VN) titrations for sera from PRV-free herds, PRV-infected pigs, and vaccinates were performed 5 by the diagnostic laboratories and veterinarians supplying the sera.
Sources of sera. Normal sera from PRV-free herds (VN antibody titers of < 1:4) were obtained from several sources. Sera from 250 pigs were obtained from a collection made October 10, 1988, on the Maddox Farm in Lometa, Texas. g This farm had been quarantined in February 1984 by the Texas Animal Health Commission.* However, the quarantine was lifted after all sera obtained on October 10, 1988, proved to be negative for PRV antibodies. Prevaccination PRV-negative sera from pigs BP, WP, 101, 102, 103, and 106 have been previously described. 9, 10 We also received 217 PRV-negative prevaccination sera. a These were obtained a,h,i,j prior to PRV(dlg92dltk) vaccine safety and efficacy tests.
Heterologous antibodies. Antisera to porcine parvovirus (PRV), swine adenovirus, swine transmissible gastroenteritis (TGE), and swine rotavirus were obtained. k In addition, antisera to swine enterovirus types 1 and 4, equine herpesvirus type 1, IBRV, pacheco herpesvirus, feline herpesvirus, bovine herpesvirus type 4 (DN599), and canine herpesvirus and a bovine sera containing a mixture of antibodies to bovine adenovirus type 3, IBRV, bovine viral diarrhea virus (BVDV), Parainfluenza virus type 3, and bovine respiratory syncytial virus were used. g Bovine antisera to foot-and-mouth disease virus VP1 polypeptide 1 and mouse monoclonal antibodies to BVDV gp56-58, m IBRV gpIII, n and PRV gI, o gII, o and gIII o were supplied.
Sera from farms with PRV-infected pigs. These sera were collected from pigs in 1988 from farms in Illinois, P Nebraska, q and Minnesota' and from pigs with VN titers > 1:8 that were culled from the Maddox farm (TX) in September 1984 (60 days after vaccination of all pigs on the farm).* Feral pig sera. Sera from seropositive feral pigs were provided. g Sera from PRV(dlg92dltk)-vaccinated pigs. Sera from pigs WP and BP vaccinated twice intramuscularly with 2 ml (8 x l0 8 PFU/pig) of PRV(dlg92dltk) have been described. l0 Sera from pigs 96, 97, 99, and 100 were supplied. k These sera were from pigs vaccinated once with PRV(dlg92dltk) and bled at 9, 16, 21, and 28 days after vaccination. Sera were obtained that had been collected from 30 pigs vaccinated 4 times. Field sera from pigs vaccinated once on Nebraska farms i were also obtained. Mouse monoclonal antibody against gIII: horseradish peroxidase conjugate. Ascites fluid containing anti-PRV g92(gIII) monoclonal antibody was prepared from hybridoma 30G3.1 in BALB/c mice. c Prior to labeling with HRPO type VJ, s the ascites fluid was partially purified with saturated ammonium sulfate. The methods for conjugating the antibody have been described. 14, 16 After preparation, the conjugate was dialyzed at 4 C against several changes of 50 mM Tris buffer, pH 7.2, and bovine serum albumin and glycerol were added to concentrations of 20 mg/ml and 50% (v/v), respectively. Aliquots (0.3 ml) of the moMCAgIII: HRPO conjugate were distributed into plastic tubes and stored at -70 C. Prior to use, the moMCAgIII: HRPO conjugate was diluted 1:700 with 2% casein-PBS-minus blocking solution. At this dilution, the addition of moMCAgIII: HRPO conjugate and substrates to the control wells containing either buffer or normal PRV-negative sera gave an optical density (OD) reading at 405 nm of about 0.90-1:l0 in 15 min at room temperature.
Principle of blocking ELISA test. Microtiter wells were precoated with PRV g92(gIII) antigen. When incubated with a swine serum sample, antibodies to PRV g92(gIII) bind to were made on a Plate Reader at 405 nm. t Results are exthe PRV antigen coating in the wells. The sample is then pressed as S/N values. removed and a moMCAgIII: HRPO conjugate is added to the wells. Antibody already bound to the PRV g92(gIII) an-
Results
tigen in the wells blocks the moMCAgIII: HRPO conjugate from binding to this antigen. After washing away all unbound materials, an ABTS f HRPO substrate solution is added to the wells. The subsequent color development is inversely proportional to the level of PRV g92(gIII) antibody present in the serum sample. Comparison of the color in the test sera wells with that of PRV-positive and PRV-negative antibody control wells accurately determines the presence of PRV g92(gIII) antibody in the test sample.
Assay procedures. The following additions were made to the microtiter plates containing PRV g92(gIII)-coated wells:
(a) 0.1 ml of buffer (negative control) solution (N) dispensed to 2 wells, (b) 0.1 ml of undiluted negative control sera dispensed to 2 wells, (c) 0.1 ml of undiluted positive control sera dispensed to 2 wells, and (d) 0.1 ml of 90 different undiluted test sera (S) placed in each of the remaining wells.
The plates were covered and incubated 1 hr at 37 C. Then, the fluid was aspirated into a waste trap, and each well was washed 3 times with about 0.3 ml of a buffered wash solution containing 0.02% Tween 20. f Following the final wash and fluid aspiration, the plates were tapped and touched to absorbent paper to remove residual wash fluid.
One-tenth milliliter of a moMCAgIII: HRPO conjugate was added to each well, and the plates were incubated for 1 hr at 37 C. The wells were washed 3 more times with the Preliminary control experiments. Wells were coated with extracts from IBRV/PRV gIII+-infected MDBK cells or IBRV(Los Angeles)-infected MDBK cells. The PBS-minus buffer, moMCAgIII: HRPO conjugate, and substrates were added, and the OD at 405 nm was measured. The OD at 405 nm of the wells containing PRV g92(gIII) antigen was about 1.0. These results were highly reproducible. Negative controls on 7 successive days were 0.97, 1.08, 0.99, 1.04, 1.04, 0.96, and 1.07. Similar results were obtained on more than 40 plates coated at different times with 4 different lots of PRV g92(gIII) antigens. The OD values of the wells containing extracts from IBRV(Los Angeles)-infected MDBK cells were less than 0.05. Similarly, normal swine sera from PRV-negative herds, or calf, horse, lamb, and mouse sera were added to wells coated with extracts from IBRV/PRV gIII+-infected MDBK cells and from IBRV(Los Angeles)-infected MDBK cells. After the addition of moMCAgIII: HRPO conjugate and ABTS substrate solutions, the OD at 405 nm of the wells coated with PRV g92(gIII) antigen was about 1.0, and that of the wells coated with extracts from IBRV(Los Angeles)-infected cells was < 0.05.
Sera from PRV-free herds. Over 300 sera from PRVfree herds were analyzed (Fig. 1) . The VN titers of these buffered Tween 20 solution as above, and then 0.1 ml of sera were < 1:4. The results of these analyses were ex-ABTS substrate solution f was added. The plates were incu-pressed as S/N ratios (PBS-minus buffer as the negative bated at room temperature for 15 min, and endpoint readings control [N]). The S/N values for these sera were mostly PRV(Indiana-Funkhauser), 9, 10 were substituted for the Twenty-nine sera from infected herds with VN titers sera from PRV-free herds, the binding of moMCAgIII: < 1:4 were available (Fig. 3) . Twenty-four of these sera HRPO conjugate was strongly blocked and the S/N had S/N values of < 0.7, and 5 sera had S/N values of ratio was <0.1. The S/N value of 0.7 was tentatively >0.7. The results show that many sera from infected chosen as the cutoff value for sera lacking PRV g92(gIII) herds with negative VN titers of < Tables 2 and 3 . All of the S/N values were >0.7, which or greater. Over 200 sera with VN titers of 1:4 or is similar to those of normal sera from PRV-free herds.
greater were tested (Fig. 2) . All except 2 of these sera In addition to the above, sera i from pigs vaccinated had S/N values of <0.7. Most of the sera had S/N once with a standard dose a were analyzed. One hundred eight, 45, and 30 sera were collected from Farm "A" at 21, 50, and 92 days postvaccination, respectively. Thirty-six and 30 sera were obtained from Farm "B" and 53 and 40 sera were collected from Farm "C" at 22 and 42 days postvaccination, respectively. All of these sera had S/N values of >0.7, indicating that they were negative for PRV g92(gIII) antibodies.
Sera from vaccinated pigs challenged with virulent PRV. Pigs were vaccinated once with a standard dose and challenged 28 days later with virulent PRV(P2208) at 5 x l0 5 TCID 50 /pig. The pigs were bled on days 21 and 36 postchallenge. The S/N values of these postchallenge sera were <0.1, indicating that they all became strongly positive for PRV g92(gIII) antibodies. 1988 PRV check test sera. The decoded results of analyses on unknown test sera in the 1988 PRV check test kit are shown in Table 4 . The g92(gIII) blocking ELISA test was performed in Houston, Texas. Check test sera Nos. 1-13 had VN titers of < 1:4 and were latex agglutination-negative. As expected, these sera were also negative in the g92(gIII) blocking ELISA test and in a commercial ELISA, GPX ELISA, and gI ELISA tests. Field sera (Nos. 15, 20, 21, 33, 34, 38, and 39) were positive in all of the tests. Serum No. 19 was collected 7 days after vaccination with a killed (Bucharest) vaccine and was negative in all tests. Sera Nos. 14, 16, and 18 were positive in the commercial ELISA and latex agglutination tests, but showed VN titers of pigs vaccinated with GPXor BUK (gI -) vaccines and were collected 8-30 days after vaccination. These sera had VN titers of < 1:4, but showed positive commercial ELISA and latex agglutination tests. The sera were, however, negative in all of the differential (GPX, gI, and g92[gIII]) ELISA tests. The remaining 3 sera (Nos. 36, 37, and 40) were collected 21 days after pigs were vaccinated with GPXand/or a killed Bucharest vaccine strain (gI -). The VN titers of these sera were PRV- 
Comparison of VN titers with titers obtained in the PRVg92(gIII) blocking ELISA test. The PRV g92(gIII)
blocking ELISA titers determined on 7 sera from the 1988 pseudorabies check test were 2-16 times greater than the VN titers ( Table 5 ).
Discussion
The PRV g92(gIII) blocking ELISA test is simple, sensitive, accurate, reproducible, and rapid. Interference did not occur from "toxic" factors in PRVnegative normal sera or in sera known to contain antibodies to various heterologous viruses. Hence, timeconsuming and laborious dilutions of test sera prior to addition to the antigen-coated wells were not required. Likewise, heat inactivation of test sera as in standard PRV neutralization tests was unnecessary. This is in contrast to the requirements of other pseudorabies diagnostic tests. 2, 4, 5, 18 The g92(gIII) blocking ELISA test utilizes only 1 monoclonal antibody conjugated to horseradish peroxidase, unlike tests that require capture antibodies or 2 monoclonal antibodies recognizing different epitopes on the same antigen. 17 Only 1 mi-Sera from pigs vaccinated 1-4 times with a standard crotiter test plate per analysis is needed. There are only dose or with 10 times the standard dose of 3 pipetting steps and 2 wash steps prior to endpoint PRV(dlg92dltk) and sera from pigs vaccinated twice readings and automatic printouts of data by a Plate with more than 1,000 times the standard dose were all Reader. Analyses on 96-well microtiter plates can be negative (S/N > 0.7) in the g92(gIII) blocking ELISA performed in less than 3 hours. The results are highly test. There were no false positives. Experimental chalreproducible.
lenge experiments showed, however, that vaccinated Whereas other PRV ELISA tests utilize a mixture pigs seroconverted to the g92(gIII)-positive status after of PRV antigens or require complicated biochemical experimental infection with g92(gIII)-positive virulent purification procedures to obtain a purified antigen to coat wells, l3 the g92(gIII) blocking ELISA test utilizes a cloned (genetically purified) PRV antigen. The preparation of this antigen from vector virus-infected cells is simple, rapid, and reproducible and does not require graded membrane filters or special equipment. Owing to the use of the blocking ELISA protocol and the specificity of the PRV g92(gIII) monoclonal antibody, there is no cross-reaction with other PRV antigens, such as gI or gII, or with the antigens of the IBRV vector or the host (MDBK) cells. In contrast, appreciable interference from antigens in extracts of IBRV(Los Angeles)-infected MDBK cells and from porcine test serum was found when indirect ELISA assays in which goat anti-pig conjugates were used instead of the mouse anti-g92(gIII) monoclonal antibody conjugate. Control antigen-coated wells in addition to PRV antigen-coated wells are often required in other tests (e.g., the verification ELISA), thereby reducing plate capacity while increasing demands on resources * VN = reciprocal of virus neutralization titer. and time. PRV strains. Further field studies on the natural exposure of PRV(dlg92dltk)-vaccinated pigs to virulent PRV strains will be useful in studies on the pathobiology of pseudorabies, e.g., the frequency with which field virus-infected vaccinated pigs seroconvert to the g92(gIII)-positive state and become latently infected with the superinfecting field strain.
Over 200 PRV-positive sera from PRV-infected herds and 16 PRV-positive sera from feral pigs with titers of 1:4 or greater were tested. Two of the sera from feral pigs gave false negative S/N values in the g92(gIII) blocking ELISA test. However, these sera had reported VN titers of 1:4 when tested 5 years prior to the g92(gIII) blocking ELISA analyses. Two sera with VN titers > 1:4 from PRV-infected herds also gave false negative results. Independent latex agglutination analyses or screening ELISA analyses were not available for these sera to confirm the PRV-positive VN titrations. The false negative values of the 2 sera from the infected farms might be attributed to VN titration In the past, the inability to distinguish between vac-* Sera were from National Veterinary Services Laboratories 1988 cinated pigs and those infected with virulent field strains pseudorabies check test (Table 4 ). k † V N = reciprocal of virus neutralization titer.
of PRV by serological tests has been a major deterrent to the use of modified-live PRV vaccines in herd cleanups and PRV eradication programs. The g92(gIII) errors, loss of antibodies during transport or storage, very low g92(gIII) antibody titers despite the presence of other detectable PRV antibodies, variant g92(gIII) antibodies not recognized by the monoclonal antibody, or to other unidentified factors.
The utility of the g92(gIII) blocking ELISA may be seen from the analyses of sera from PRV-infected herds with VN titers < 1:4 ( Fig. 3) . Twenty-four of 29 sera exhibited positive g92(gIII) antibody titers (S/N < 0.7) despite the fact that the VN titers were negative. Similarly, the unknown sera Nos. 16, 18, and 21 analyzed in the PRV check test had VN titers of 1:4 or less but were positive in the g92(gIII) blocking ELISA test. That they, in fact, contained PRV antibodies was indicated by their PRV-positive latex agglutination and commercial verification ELISA analyses.
Some of the check test sera (Nos. 17, 22-24, 31, 32, and 35) from vaccinated pigs were PRV antibody-positive in the latex agglutination and verification ELISA tests but negative in the differential g92(gIII) blocking ELISA test. However, VN titers of these sera were < 1: 4, and the sera were also negative in the differential gI and GPX ELISA tests. It is not unexpected to find that all 3 differential antibody tests may be negative on sera scoring positive in latex agglutination and verification ELISA tests. The latex agglutination and verification ELISA tests involve detection of the sum total of all PRV antibodies in crude extracts from PRV-infected cells, whereas the g92(gIII) blocking ELISA and other differential antibody tests involve detection of only 1 antibody. However, the potential for greater sensitivity produced by using crude PRV antigen preparations in screening ELISA tests may be counterbalanced by the need for more stringent controls. Titers of 7 sera obtained with the PRV g92(gIII) blocking ELISA test were 2-16 times greater than the VN titers of the same sera. These results further underline the sensitivity of the PRV g92(gIII) blocking ELISA test.
The comparative accuracy of the g92(gIII) blocking ELISA test may be noted from the PRV check test.
blocking ELISA test in conjunction with the PRV(dlg92dltk) vaccine can play a dominant role in the cleanup of infected herds. In applying the g92(gIII) blocking ELISA test, all sera with S/N values <0.7 should be considered positive for g92(gIII) antibodies. Taking into account errors inherent in all measurements, it may be desirable to retest sera "in the grey zone" of S/N values of about 0.65-0.75. If the result is reproducible, another sample from the same animal could be analyzed. If the user wishes to err on the side of caution, any pigs with sera showing borderline S/N values might be culled in an eradication program.
Aside from the cited merits of the g92(gIII) blocking ELISA test, the PRV g92(gIII) marker may have advantages over other markers. The PRV glycoprotein g92(gIII) is a major immunogen. l, 3 Other markers, such as GPX and gI, are minor glycoproteins of PRV-infected cells. The GPX glycoprotein is absent from both the envelope of PRV particles and the membrane of PRV-infected cells. Thus, antibodies, to g92(gIII) represent a larger fraction of the total PRV antibodies than the GPX and gI antibodies and may be a more reliable indicator of PRV infection. 
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